Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance

BioNTech SE - ADRTrade
Roundhill Innov-100 0DTE Covered Call Strat ETFTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? BioNTech SE - ADR trades at $93.4 (market cap $23.31B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.83. Which is the better fit depends on your goals.

BNTXQDTE
Market Cap
$23.31B
Sector
HealthIncome / Options Overlay
52-Week High
$119.34$36.60
52-Week Low
$83.89$26.85
Enterprise Value
$6.60B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.

The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.

Roundhill Innov-100 0DTE Covered Call Strat ETF

QDTE trades at $29.835, up 0.62% with a bearish technical signal from moving averages. The ETF faces significant concerns about its distribution strategy, with recent analysis highlighting that its high yield is funded by return of capital rather than actual earnings, leading to persistent NAV erosion. Technical indicators show resistance at $30 with support at $29, while RSI levels suggest mixed momentum signals.

The outlook remains cautious as the fund's structural issues with NAV depletion outweigh the appeal of weekly distributions. Investment opportunity exists only for those understanding the return-of-capital mechanics, while risks include continued underperformance and yield sustainability concerns in changing volatility environments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Roundhill Innov-100 0DTE Covered Call Strat ETF

QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.

Read more on QDTE